Logo

American Heart Association

  53
  0


Final ID:

Commentary: Screening for Cardiac Amyloid

  • Ahmad, Faraz  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Faraz Ahmad: DO have relevant financial relationships ; Research Funding (PI or named investigator):Pfizer:Past (completed) ; Consultant:AstraZeneca:Past (completed) ; Speaker:AstraZeneca:Past (completed) ; Speaker:Alnylam:Past (completed) ; Consultant:Alnylam Pharmceuticals:Active (exists now) ; Research Funding (PI or named investigator):Abiomed/Johnson and Johnson:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):Atman Health:Past (completed) ; Research Funding (PI or named investigator):Tempus:Active (exists now) ; Research Funding (PI or named investigator):Atman Health :Past (completed)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Rewriting the Code for Cardiac Amyloid: Novel Identification, Treatment, and Cure

Monday, 11/10/2025 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Commentary: Gene Therapy for Cardiac Amyloid

Grogan Martha, Grodin Justin, Ambardekar Amrut

Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM)

Fontana Marianna, Kar Soumitra, Revanna Manjunatha, Sarswat Nitasha, Tsujita Kenichi, Maurer Mathew, Garcia-pavia Pablo, Grogan Martha, Shah Sanjiv, Engelmann Mads, Hovingh G. Kees, Kristen Arnt, Lim-watson Michelle, Malling Brian

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available